KPV vs Afamelanotide
Both KPV and Afamelanotide are used for skin. Here's how their evidence, dosing, and regulatory status actually compare.
KPV
Evidence C+α-MSH Tripeptide KPV
The C-terminal tripeptide of α-MSH with documented anti-inflammatory activity in IBD and dermatitis preclinical models. Frequently delivered orally and topically.
View full KPV profile →Afamelanotide
Evidence AAfamelanotide (Scenesse)
An FDA-approved selective MC1R agonist used to increase eumelanin density in erythropoietic protoporphyria patients. Off-label cosmetic tanning use is widespread internationally.
View full Afamelanotide profile →Side-by-Side
| Attribute | KPV | Afamelanotide |
|---|---|---|
| Evidence Grade | C+ | A |
| FDA Status | Not FDA-approved — research peptide | FDA-approved (2019) for erythropoietic protoporphyria (EPP) |
| Typical Dose | 200–500 mcg orally or topical (research only) | 16 mg subcutaneous implant every 2 months (clinical use) |
| Clinics Indexed | 26 | 14 |
| Categories | anti-inflammatory, gut-health, skin | skin |
Key reported benefits — KPV
- ✓GI inflammation reduction
- ✓Skin inflammation reduction
- ✓Antimicrobial activity
Key reported benefits — Afamelanotide
- ✓MC1R-selective tanning
- ✓FDA-approved for EPP
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.